European innovation is firmly rooted in the relationship between science and business. At a recent specialist seminar, organized by a European Union-funded ScanBalt network, leading European experts offered their wisdom on the best ways to develop and exploit intellectual property in the biosciences, according to a European Commission statement.
Drilling to core of the innovation business
With the first round of seminars on Intellectual Property Strategies in Bioscience now complete, it is time to take stock, says ScanBalt. Innovation is one thing, but being able to manage the fruits of these new ideas and developments is where Europe needs to look long and hard, it was revealed at the third and most recent seminar in the series, held recently in the Hanseatic city of Wismar.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze